D
D. Voliotis
Researcher at Bayer Corporation
Publications - 34
Citations - 17725
D. Voliotis is an academic researcher from Bayer Corporation. The author has contributed to research in topics: Sorafenib & Hepatocellular carcinoma. The author has an hindex of 20, co-authored 33 publications receiving 15241 citations. Previous affiliations of D. Voliotis include Bayer HealthCare Pharmaceuticals & Bayer.
Papers
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
Dirk Strumberg,Heike Richly,Ralf A. Hilger,Norbert Schleucher,Sonke Korfee,Mitra Tewes,Markus Faghih,E. Brendel,D. Voliotis,C. G. Haase,Brian Schwartz,Ahmad Awada,Rudolf Voigtmann,Max E. Scheulen,Siegfried Seeber +14 more
TL;DR: Based on the results of this study, BAY 43-9006 at 400 mg bid continuous is recommended for ongoing and future studies and was well tolerated and appeared to provide some clinical benefits.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Jordi Bruix,Jean-Luc Raoul,Morris Sherman,Vincenzo Mazzaferro,Luigi Bolondi,Antonio Craxì,Peter R. Galle,Armando Santoro,Michel Beaugrand,Angelo Sangiovanni,Camillo Porta,Guido Gerken,Jorge A. Marrero,Andrea Nadel,Michael Shan,M. Moscovici,D. Voliotis,Josep M. Llovet +17 more
TL;DR: The SHARP trial as discussed by the authors showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage and prior therapy.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
Ann-Lii Cheng,Zhongzhen Guan,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Tsai Sheng Yang,Won Young Tak,Hongming Pan,Shiying Yu,Jianming Xu,Fang Fang,Jessie Zou,Giuseppe Lentini,D. Voliotis,Yoon-Koo Kang +15 more
TL;DR: Experimental analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status, and the efficacy and safety profiles in the subpopulations described were comparable with those in the overall study population.